Blood pressure control in patients with chronic renal insufficiency in Spain: A cross-sectional study

Journal of Hypertension

Volumn 24, Issue 2, 2006, Pages 395-402

  Marín, Rafael ^a   Fernández Vega, Francisco ^a   Gorostidi, Manuel ^b   Ruilope, Luis M ^c   Diez, Javier ^d   Praga, Manuel ^c   Herrero, Pablo ^a   Alcázar, Jose M ^c   Laviades, Concepción ^e   Aranda, Pedro ^f  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b HOSPITAL SAN AGUSTÍN   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

^e HOSPITAL SAN JORGE   (Spain)

^f HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

Antihypertensive treatment; Blood pressure control; Chronic renal insufficiency; Progression of renal disease; Proteinuria

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMORBIDITY; DIABETIC NEPHROPATHY; FEMALE; HUMAN; KIDNEY DISEASE; MALE; MULTICENTER STUDY; NEPHROLOGY; OUTPATIENT; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPAIN;

EID: 33644789699     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000202819.48577.a1     Document Type: Article

References (29)

1. Stengel B, Billon S, van Dijk PCW, Jager KJ, Dekker FW, Simpson K, et al., on behalf of the ERA-EDTA Registry Committee. Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. Nephrol Dial Transplant 2003; 18:1824-1833.
2. Amenábar JJ, García-López F, Robles NR, Saracho R, por el Comité de Registros de la SEN. Informe de diálisis y trasplante de la Sociedad Española de Nefrología y Registros Autonómicos correspondientes al año 1999. Netrología 2001; 21:246-252.
3. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal disease. Lancet 2001; 357:1601-1608.
4. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, et al., for the Modification of Diet in Renal Disease (MDRD) Study Group. Blood pressure control, proteinuria, and the progression of renal disease. Ann Intern Med 1995; 123:754-762.
5. Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease study. Ann Intern Med 2005; 142:342-351.
6. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The seventh report of the Joint National Committee on Prevention, Detection. Evaluation and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.
7. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-1053.
8. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43(Suppl 1):S1-S290.
9. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65:2309-2320.
10. Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J, et al., for the African American Study of Kidney Disease and Hypertension study group. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease. Results of the African American Study of Kidney Disease and Hypertension. Arch Intern Med 2005; 165:947-953.
11. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
12. Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. 'Gruppo Italiano di Studi Epidemiologici in Nefrologia' (GISEN). Kidney Int 1998; 53:1209-1216.
13. Marín R, Ruilope LM, Aljama P, Aranda P, Segura J, Diez J, on behalf of the investigators of the ESPIRAL study. A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. J Hypertens 2001; 19:1871-1876.
14. Coresh J, Wei GL, McQuillan G, Brancati FL, Levey AS, Jones C, et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States. Arch Intern Med 2001; 161:1207-1216.
15. O'Brien E, Asmar R, Beilin L, Imai Y, Mancia G, Mengden T, et al., on behalf of the European Society of Hypertension Working Group on Blood Pressure Monitoring. Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens 2005; 23:697-701.
16. Zoccali C, Mallamaci F, Finocchiaro P. Atherosclerotic renal artery stenosis: epidemiology, cardiovascular outcomes, and clinical prediction rules. J Am Soc Nephrol 2002; 13 (Suppl 3):S179-S183.
17. Burden R, Dasgupta I. How good are nephrologists at controlling blood pressure in renal patients? Nephrol Dial Transplant 2000; 15:440-441.
18. Banegas JR, Segura J, Ruilope LM, Luque M, Garcia-Robles R, Campo C, et al., on behalf of the CLUE Study Group Investigators. Blood pressure control and physician management of hypertension in hospital hypertension units in Spain. Hypertension 2004; 43:1338-1344.
19. Mancia G, Pessina AC, Trimarco B, Grassi G. on behalf of the SILVIA (Studio Italiano Longitudinale sulla Valutazione della Ipertensione Arteriosa nel 2000) Study Group. J Hypertens 2004; 22:2387-2396.
20. Bakris GL. Protecting renal function in the hypertensive patient: clinical guidelines. Am J Hypertens 2005; 18:112S-119S.
21. De Nicola L, Minutolo R, Bellizzi V, Zoccali C, Cianciaruso B, Andreucci VE, et al. Achievement of target blood pressure levels in chronic kidney disease: a salty question? Am J Kidney Dis 2004; 43:782-795.
22. Jafar TH, Schmid CH, Stark PC, Toto R, Remuzzi G, Ruggeneti P, et al. The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis. Nephrol Dial Transplant 2003; 18:2047-2053.
23. Israni A, Korzelius C, Townsed R, Mesler D. Management of chronic kidney disease in an academic primary care clinic. Am J Nephrol 2002; 23:47-54.
24. Nissenson AR, Collins AJ, Hurley J, Petersen H, Pereira BJG, Steinberg EP. Opportunities for improving the care of patients with chronic renal insufficiency: current practice patterns. J Am Soc Nephrol 2001; 12:1713-1720.
25. Hsu CY, Bates DW, Kuperman GJ, Curhan GC. Blood pressure and angiotensin converting enzyme inhibitor use in hypertensive patients with chronic renal insufficiency. Am J Hypertens 2001; 14:1219-1225.
26. Schwenger V, Ritz E. Audit of antihypertensive treatment in patients with renal failure. Nephrol Dial Transplant 1998; 13:3091-3095.
27. Anavekar NS, McMurray JJV, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351:1285-1295.
28. Weiner DE, Tighiouart H, Stark PC, Amin MG, MacLeod B, Griffith JL, et al. Kidney disease as a risk factor to recurrent cardiovascular disease and mortality. Am J Kidney Dis 2004; 44:198-206.
29. Hsu C-Y, Chertow GM, Curhan GC. Methodological issues in studying the epidemiology of mild to moderate chronic renal insufficiency. Kidney Int 2002; 61:1567-1576.